Vlahovic highlighted several options that can help improve the appearance of dystrophic nails as they recover or grow back: ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

The Company's BLA for pz-cel was previously accepted for Priority Review by the FDA for patients with RDEB. Abeona may be ...

At the end of the trial, lamotrigine was found to reduce stiffness—the main symptom of non-dystrophic myotonia—by around the ...

Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...

Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.

Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa.